Several neutralizing antibodies against IL-33 are currently in early phases of clinical development as therapeutic approaches for asthma, COPD (chronic obstructive pulmonary disease), atopic dermatitis, or chronic rhinosinusitis with nasal polyps (Table 2). Here, IL33 is linked to asthma.